Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2017

Open Access 01-12-2017 | Review

Targeting psychologic stress signaling pathways in Alzheimer’s disease

Authors: Hunter S. Futch, Cara L. Croft, Van Q. Truong, Eric G. Krause, Todd E. Golde

Published in: Molecular Neurodegeneration | Issue 1/2017

Login to get access

Abstract

Alzheimer’s Disease (AD) is the most prevalent progressive neurodegenerative disease; to date, no AD therapy has proven effective in delaying or preventing the disease course. In the search for novel therapeutic targets in AD, it has been shown that increased chronic psychologic stress is associated with AD risk. Subsequently, biologic pathways underlying psychologic stress have been identified and shown to be able to exacerbate AD relevant pathologies. In this review, we summarize the literature relevant to the association between psychologic stress and AD, focusing on studies investigating the effects of stress paradigms on transgenic mouse models of Amyloid-β (Aβ) and tau pathologies. In recent years, a substantial amount of research has been done investigating a key stress-response mediator, corticotropin-releasing hormone (CRH), and its interactions with AD relevant processes. We highlight attempts to target the CRH signaling pathway as a therapeutic intervention in these transgenic mouse models and discuss how targeting this pathway is a promising avenue for further investigation.
Literature
1.
2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12:459–509.
2.
Aguzzi A, O’Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov. 2010;9:237–48.CrossRefPubMed
3.
4.
5.
Iacono D, Volkman I, Nennesmo I, Pedersen NL, Fratiglioni L, Johansson B, et al. Neuropathologic assessment of dementia markers in identical and fraternal twins: AD and non-AD pathologies in older twins. Brain Pathol. 2014;24:317–33.CrossRefPubMedPubMedCentral
6.
7.
Kaup AR, Byers AL, Falvey C, Simonsick EM, Satterfield S, Ayonayon HN, et al. Trajectories of depressive symptoms in older adults and risk of dementia. JAMA Psychiatry. 2016;73:525.CrossRefPubMedPubMedCentral
8.
Wilson RS, Evans DA, Bienias JL, De Leon CM, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer’s disease. Neurology. 2003;61:1479–85.CrossRefPubMed
9.
Johansson L, Guo X, Duberstein PR, Hällström T, Waern M, Östling S, et al. Midlife personality and risk of Alzheimer disease and distress a 38-year follow-up. Neurology. 2014;83:1538–44.CrossRefPubMed
10.
Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 2015;jnnp-2015-310548.
11.
Andel R, Crowe M, Hahn EA, Mortimer JA, Pedersen NL, Fratiglioni L, et al. Work-related stress may increase the risk of vascular dementia. J Am Geriatr Soc. 2012;60:60–7.CrossRefPubMed
12.
Tsolaki M, Papaliagkas V, Kounti F, Messini C, Boziki M, Anogianakis G, et al. Severely stressful events and dementia: a study of an elderly Greek demented population. Psychiatry Res. 2010;176:51–4.CrossRefPubMed
13.
Bangen KJ, Clark AL, Werhane M, Edmonds EC, Nation DA, Evangelista N, et al. Cortical amyloid burden differences across empirically-derived mild cognitive impairment subtypes and interaction with APOE ɛ4 genotype. Brandt J, editor. J. Alzheimers Dis. 2016;52:849–61.CrossRef
14.
Loring DW, Goldstein FC, Chen C, Drane DL, Lah JJ, Zhao L, et al. False-positive error rates for reliable digit span and auditory verbal learning test performance validity measures in amnestic mild cognitive impairment and early Alzheimer disease. Arch Clin Neuropsychol. 2016;31:313–31.CrossRefPubMedPubMedCentral
15.
Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci. 2002;23:71–7.CrossRefPubMed
16.
Hauger RL, Risbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci. 2009;1179:120–43.CrossRefPubMedPubMedCentral
17.
Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord.-Drug targets former. Curr. Drug targets-CNS Neurol. Disord. 2006;5:453–79.
18.
Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. In: Terjung R, editor. Compr. Physiol. [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2016 [cited 2016 Sep 30]. p. 603–21. Available from: http://​doi.​wiley.​com/​10.​1002/​cphy.​c150015.
19.
Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983;305:325–7.CrossRefPubMed
20.
Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, et al. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A. 1994;91:8777–81.CrossRefPubMedPubMedCentral
21.
Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995;15:6340–50.PubMed
22.
Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol. 2000;428:191–212.CrossRefPubMed
23.
Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Vogl AM, et al. Glutamatergic and dopaminergic neurons mediate Anxiogenic and anxiolytic effects of CRHR1. Science. 2011;333:1903–7.CrossRefPubMed
24.
Sapolsky RM. Stress and the brain: individual variability and the inverted-U. Nat Neurosci. 2015;18:1344–6.CrossRefPubMed
25.
Bamberger CM, Bamberger A. The peripheral CRH/urocortin system. Ann N Y Acad Sci. 2000;917:290–6.CrossRefPubMed
26.
Inda C, dos Santos Claro PA, Bonfiglio JJ, Senin SA, Maccarrone G, Turck CW, et al. Different cAMP sources are critically involved in G protein–coupled receptor CRHR1 signaling. J Cell Biol. 2016;214:181–95.CrossRefPubMedPubMedCentral
27.
28.
Hoare SRJ, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, et al. Ligand affinity for amino-terminal and Juxtamembrane domains of the Corticotropin releasing factor type I receptor: Regulation by G-protein and Nonpeptide antagonists. Biochemistry (Mosc). 2004;43:3996–4011.CrossRef
29.
Höschl C, Hajek T. Hippocampal damage mediated by corticosteroids—a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci. 2001;251:81–8.CrossRef
30.
Sousa N, Lukoyanov NV, Madeira MD, Almeida OFX, Paula-Barbosa MM. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience. 2000;97:253–66.CrossRefPubMed
31.
Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. 2009;10:434–45.CrossRefPubMed
32.
Pardon M-C, Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders? Neurosci Biobehav Rev. 2008;32:1103–20.CrossRefPubMed
33.
Landfield PW, Blalock EM, Chen K-C, Porter NM. A new glucocorticoid hypothesis of brain aging: implications for Alzheimer’s disease. Curr Alzheimer Res. 2007;4:205–12.CrossRefPubMedPubMedCentral
34.
Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, et al. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer’s type. Neurobiol Aging. 2015;36:601–7.CrossRefPubMed
35.
Ennis GE, An Y, Resnick SM, Ferrucci L, O’Brien RJ, Moffat SD. Long-term cortisol measures predict Alzheimer disease risk. Neurology. 2016:10–1212.
36.
Green KN. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2006;26:9047–56.CrossRefPubMed
37.
Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, et al. The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry. 2009;14:95–105.CrossRefPubMed
38.
Pinheiro S, Silva J, Mota C, Vaz-Silva J, Veloso A, Pinto V, et al. Tau Mislocation in glucocorticoid-triggered hippocampal pathology. Mol Neurobiol. 2016;53:4745–53.CrossRefPubMed
39.
Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, Takashima A, et al. Stress acts cumulatively to precipitate Alzheimer’s disease-like tau pathology and cognitive deficits. J Neurosci. 2011;31:7840–7.CrossRefPubMed
40.
Baglietto-Vargas D, Medeiros R, Martinez-Coria H, LaFerla FM, Green KN. Mifepristone alters amyloid precursor protein processing to preclude amyloid Beta and Also reduces tau pathology. Biol Psychiatry. 2013;74:357–66.CrossRefPubMedPubMedCentral
41.
Näsman B, Olsson T, Fagerlund M, Eriksson S, Viitanen M, Carlström K. Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer’s disease. Biol Pyschiatry. 1996;39:311–8.CrossRef
42.
Bernardi F, Lanzone A, Cento RM, Spada RS, Pezzani I, Genazzani AD, et al. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer’s disease and vascular dementia. Eur J Endocrinol. 2000;142:466–71.CrossRefPubMed
43.
Dong H, Wang S, Zeng Z, Li F, Montalvo-Ortiz J, Tucker C, et al. Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice. Psychopharmacology. 2014;231:4711–22.CrossRefPubMedPubMedCentral
44.
Park H-J, Ran Y, Jung JI, Holmes O, Price AR, Smithson L, et al. The stress response neuropeptide CRF increases amyloid- production by regulating -secretase activity. EMBO J. 2015;34:1674–86.CrossRefPubMedPubMedCentral
45.
Chen Y, Peng Y, Che P, Gannon M, Liu Y, Li L, et al. α 2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc. Natl. Acad. Sci. 2014;111:17296–301.
46.
Thathiah A, Horré K, Snellinx A, Vandewyer E, Huang Y, Ciesielska M, et al. β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer’s disease. Nat. Med. 2012;19:43–9.
47.
Kang JE, Cirrito JR, Dong H, Csernsnsky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci. 2007;104:10673–8.CrossRefPubMedPubMedCentral
48.
Dong H, Yuede CM, Yoo H-S, Martin MV, Deal C, Mace AG, et al. Corticosterone and related receptor expression are associated with increased β-amyloid plaques in isolated Tg2576 mice. Neuroscience. 2008;155:154–63.CrossRefPubMedPubMedCentral
49.
Dong H, Murphy KM, Meng L, Montalvo-Ortiz J, Zeng Z, Kolber BJ, et al. Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2012;28:579–92.PubMedPubMedCentral
50.
Ray B, Gaskins DL, Sajdyk TJ, Spence JP, Fitz SD, Shekhar A, et al. Restraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid-β precursor protein and amyloid-β peptide but have divergent effects on brain-derived neurotrophic factor and pre-synaptic proteins in the prefrontal cortex of rats. Neuroscience. 2011;184:139–50.CrossRefPubMedPubMedCentral
51.
Campbell SN, Zhang C, Roe AD, Lee N, Lao KU, Monte L, et al. Impact of CRFR1 ablation on amyloid-β production and accumulation in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2015;45:1175–84.PubMedPubMedCentral
52.
Iqbal K, Liu F, Gong C-X. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2015;12:15–27.CrossRefPubMed
53.
Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer’s disease. Brain Res. 2013;1529:200–8.CrossRefPubMedPubMedCentral
54.
Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, Brunden KR, et al. Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a Corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of Tauopathy. J Neurosci. 2011;31:14436–49.CrossRefPubMedPubMedCentral
55.
Rissman RA, Lee K-F, Vale W, Sawchenko PE. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci. 2007;27:6552–62.CrossRefPubMed
56.
Campbell SN, Zhang C, Monte L, Roe AD, Rice KC, Taché Y, et al. Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor. J Alzheimers Dis. 2015;43:967–76.PubMedPubMedCentral
57.
Filipcik P, Novak P, Mravec B, Ondicova K, Krajciova G, Novak M, et al. Tau protein phosphorylation in diverse brain areas of normal and CRH deficient mice: up-Regulation by stress. Cell Mol Neurobiol. 2012;32:837–45.CrossRefPubMed
58.
Le MH, Weissmiller AM, Monte L, Lin PH, Hexom TC, Natera O, et al. Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport. Ryabinin AE, editor. PLOS ONE. 2016;11:e0147250.
59.
Rissman RA, Staup MA, Lee AR, Justice NJ, Rice KC, Vale W, et al. Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation. Proc Natl Acad Sci. 2012;109:6277–82.CrossRefPubMedPubMedCentral
60.
Kvetnansky R, Novak P, Vargovic P, Lejavova K, Horvathova L, Ondicova K, et al. Exaggerated phosphorylation of brain tau protein in CRH KO mice exposed to repeated immobilization stress. Stress. 2016;19:395–405.CrossRefPubMed
61.
Kehne JH, Cain CK. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther. 2010;128:460–87.CrossRefPubMedPubMedCentral
62.
Lowery EG, Thiele TE. Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism. CNS Neurol. Disord.-Drug targets former. Curr. Drug targets-CNS Neurol. Disord. 2010;9:77–86.
63.
Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R, et al. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology. 2015;40:1053–63.CrossRefPubMed
64.
Zhang C, Kuo C-C, Moghadam SH, Monte L, Campbell SN, Rice KC, et al. Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer’s disease. Alzheimers Dement. 2016;12:527–37.CrossRefPubMed
65.
Contoreggi C, Lee MR, Chrousos G. Addiction and corticotropin-releasing hormone type 1 receptor antagonist medications: Antistress drugs as treatments for addiction. Ann N Y Acad Sci. 2013;1282:107–18.CrossRefPubMed
66.
67.
Réus GZ, Titus SE, Abelaira HM, Freitas SM, Tuon T, Quevedo J, et al. Neurochemical correlation between major depressive disorder and neurodegenerative diseases. Life Sci. 2016;158:121–9.CrossRefPubMed
68.
Bao A-M, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev. 2008;57:531–53.CrossRefPubMed
69.
Austin KW, Ameringer SW, Cloud LJ. An integrated review of psychological stress in Parkinson’s disease: biological mechanisms and symptom and health outcomes. Park Dis. 2016;2016:1–15.CrossRef
70.
Hou G, Tian R, Li J, Yuan T-F. Chronic stress and Parkinson’s disease. CNS Neurosci Ther. 2014;20:1–2.CrossRefPubMed
71.
Smith LK, Jadavji NM, Colwell KL, Katrina Perehudoff S, Metz GA. Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson’s disease. Eur J Neurosci. 2008;27:2133–46.CrossRefPubMedPubMedCentral
72.
Lauretti E, Di Meco A, Merali S, Praticò D. Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson’s disease. Transl Psychiatry. 2016;6:e733.CrossRefPubMedPubMedCentral
73.
Kibel A, Drenjančević-Perić I. Impact of glucocorticoids and chronic stress on progression of Parkinson’s disease. Med Hypotheses. 2008;71:952–6.CrossRefPubMed
74.
Wu Q, Yang X, Zhang Y, Zhang L, Feng L. Chronic mild stress accelerates the progression of Parkinson’s disease in A53T α-synuclein transgenic mice. Exp Neurol. 2016;285:61–71.CrossRefPubMed
75.
Sugama S, Kakinuma Y. Loss of dopaminergic neurons occurs in the ventral tegmental area and hypothalamus of rats following chronic stress: possible pathogenetic loci for depression involved in Parkinson’s disease. Neurosci Res. 2016;111:48–55.CrossRefPubMed
76.
Sugama S, Sekiyama K, Kodama T, Takamatsu Y, Takenouchi T, Hashimoto M, et al. Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: possible role of chronic stress in the onset of Parkinson’s disease. Brain Behav Immun. 2016;51:39–46.CrossRefPubMed
77.
Mo C, Renoir T, Pang TYC, Hannan AJ. Short-term memory acquisition in female Huntington’s disease mice is vulnerable to acute stress. Behav Brain Res. 2013;253:318–22.CrossRefPubMed
78.
Mo C, Renoir T, Hannan AJ. Effects of chronic stress on the onset and progression of Huntington’s disease in transgenic mice. Neurobiol Dis. 2014;71:81–94.CrossRefPubMed
79.
80.
Stuller KA, Jarrett B, DeVries AC. Stress and social isolation increase vulnerability to stroke. Exp Neurol. 2012;233:33–9.CrossRefPubMed
81.
van der Linde RM, Dening T, Stephan BCM, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry. 2016;209:366–77.CrossRefPubMedPubMedCentral
82.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102.CrossRefPubMed
83.
Lee K-W, Kim J-B, Seo J-S, Kim T-K, Im J-Y, Baek I-S, et al. Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. J Neurochem. 2009;108:165–75.CrossRefPubMed
84.
Huang H-J, Liang K-C, Ke H-C, Chang Y-Y, Hsieh-Li HM. Long-term social isolation exacerbates the impairment of spatial working memory in APP/PS1 transgenic mice. Brain Res. 2011;1371:150–60.CrossRefPubMed
85.
Borchelt DR, Ratovitski T, Van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939–45.CrossRefPubMed
86.
Rothman SM, Herdener N, Camandola S, Texel SJ, Mughal MR, Cong W-N, et al. 3xTgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress. Neurobiol. Aging. 2012;33:830.e1–830.e12.
87.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39:409–21.CrossRefPubMed
88.
Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci. 1994;14:2579–84.PubMed
89.
Baglietto-Vargas D, Chen Y, Suh D, Ager RR, Rodriguez-Ortiz CJ, Medeiros R, et al. Short-term modern life-like stress exacerbates Aβ-pathology and synapse loss in 3xTg-AD mice. J Neurochem. 2015;134:915–26.CrossRefPubMedPubMedCentral
90.
Justice NJ, Huang L, Tian J-B, Cole A, Pruski M, Hunt AJ, et al. Posttraumatic stress disorder-like induction elevates -amyloid levels, which directly activates Corticotropin-releasing factor neurons to exacerbate stress responses. J Neurosci. 2015;35:2612–23.CrossRefPubMedPubMedCentral
91.
Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S Tauopathy mouse model. Neuron. 2007;53:337–51.CrossRefPubMed
Metadata
Title
Targeting psychologic stress signaling pathways in Alzheimer’s disease
Authors
Hunter S. Futch
Cara L. Croft
Van Q. Truong
Eric G. Krause
Todd E. Golde
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2017
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/s13024-017-0190-z

Other articles of this Issue 1/2017

Molecular Neurodegeneration 1/2017 Go to the issue

Review

NADPH oxidase in brain injury and neurodegenerative disorders

Research article

Quantitative proteomic analysis of Parkin substrates in Drosophila neurons

Correction

Correction to: Gene-environment interaction between lead and Apolipoprotein E4 causes cognitive behavior deficits in mice

Research article

Transient IKK2 activation in astrocytes initiates selective non-cell-autonomous neurodegeneration

Research article

Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer’s disease

Review

TREM2 in Neurodegenerative Diseases